SPHS has been one to watch since Friday. Now at .64 low with so much more room to run, do keep an eye on this one. Expected to move to at least $4.00 based on Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Plan.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.